Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Daewoong gets patent of Nabota as migraine drug in US

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of...

Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...

Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...

Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...

Daewoong Pharma wins permission from Singapore for Nabota

South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...

Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Ja...

Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukrai...